fig3
From: HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
![HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer](https://image.oaes.cc/a023a67a-8b6e-48b7-8917-2f7dea8e3f8d/4466.fig.3.jpg)
Figure 3. Suitable targets for combination therapies with HDAC inhibitors in CRPC. HDAC: Histone deacetylase; CRPC: castration-resistant prostate cancer; MEK: MAPK/ERK kinase; TRAIL: TNF-related apoptosis-inducing ligand.